Related Articles
Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model
Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations
First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer
Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor‑tyrosine kinase inhibitor via the PI3K/AKT pathway in non‑small cell lung cancer cells<em> in vitro</em>
Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H